OKYO Pharma Limited announces U.S.5.74 million Global Private Placement and investment by directors and members of senior management
OKYO Stock | USD 1.02 0.02 1.92% |
About 61% of OKYO Pharma's investor base is looking to short. The analysis of the overall investor sentiment regarding OKYO Pharma Ltd suggests that many traders are alarmed. OKYO Pharma's investing sentiment overview a quick insight into current market opportunities from investing in OKYO Pharma Ltd. Many technical investors use OKYO Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
OKYO |
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE...
Read at globenewswire.com
OKYO Pharma Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards OKYO Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
OKYO Pharma Fundamental Analysis
We analyze OKYO Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OKYO Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OKYO Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
OKYO Pharma is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
OKYO Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with OKYO Pharma stock to make a market-neutral strategy. Peer analysis of OKYO Pharma could also be used in its relative valuation, which is a method of valuing OKYO Pharma by comparing valuation metrics with similar companies.
Peers
OKYO Pharma Related Equities
CVKD | Cadrenal Therapeutics, | 7.35 | ||||
COEP | Coeptis Therapeutics | 5.26 | ||||
FHTX | Foghorn Therapeutics | 2.57 | ||||
QNRX | Quoin Pharmaceuticals | 1.69 | ||||
CMND | Clearmind Medicine | 1.56 | ||||
UNCY | Unicycive Therapeutics | 1.47 | ||||
SNTI | Senti Biosciences | 0.93 | ||||
ANEB | Anebulo Pharmaceuticals | 0.70 | ||||
CDIO | Cardio Diagnostics | 3.23 | ||||
VRAX | Virax Biolabs | 4.83 | ||||
CADL | Candel Therapeutics | 4.85 |
Check out OKYO Pharma Hype Analysis, OKYO Pharma Correlation and OKYO Pharma Performance. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Return On Assets (2.92) | Return On Equity (29.69) |
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.